Novo Nordisk ADR (NVO) concluded trading on 01/03/24 at a closing price of $103.62, with 3.72 million shares of worth about $385.19 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 29.53% during that period and on Wednesday the price saw a gain of about 1.48%. Currently the company’s common shares owned by public are about 3.42B shares, out of which, 3.39B shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 27 analysts are covering the NVO stock and their offered price forecasts bring an average price target of $734.28. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $875.00 and could fall to a lowest price of $360.00. The stock’s current price level is 1.93% above of average price target set by the analysts, while a rise to estimated low would result in gain of 71.22% for the stock. However, touching the estimated high of $875.00 would mean a gain of 88.16% for the stock.
Novo Nordisk ADR (NYSE: NVO) started trading at $102.05, below -$0.06 from concluding price of the previous day. However, the stock later moved at a day high price of 103.84, or with a gain of 1.48%. Stock saw a price change of 0.92% in past 5 days and over the past one month there was a price change of 3.21%. Year-to-date (YTD), NVO shares are showing a performance of 0.16% which increased to 53.13% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $65.05 but also hit the highest price of $105.69 during that period. The average intraday trading volume for Novo Nordisk ADR shares is 4.47 million. The stock is currently trading 3.60% above its 20-day simple moving average (SMA20), while that difference is up 3.73% for SMA50 and it goes to 16.57% higher than SMA200.
Novo Nordisk ADR (NYSE: NVO) currently have 3.42B outstanding shares and institutions hold larger chunk of about 8.88% of that.
The stock has a current market capitalization of $350.81B and its 3Y-monthly beta is at 0.41. PE ratio of stock for trailing 12 months is 43.06, while it has posted earnings per share of $2.41 in the same period. Its PEG reads 15.38 and has Quick Ratio of 0.65 while making debt-to-equity ratio of 0.29. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NVO, volatility over the week remained 1.30% while standing at 1.38% over the month.
Analysts are in expectations that Novo Nordisk ADR (NVO) stock would likely to be making an EPS of $0.65 in the current quarter, while forecast for next quarter EPS is $0.83 and it is $3.24 for next year. For the current quarter EPS, analysts have given the company a lowest target $0.65 which is $0.66 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $0.44 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 47.85% while it is estimated to increase by 21.13% in next year. EPS is likely to shrink at an annualized rate of 2.80% for next 5-years, compared to annual growth of 8.17% made by the stock over the past 5-years.
Analysts at 27 brokerage firms have issued recommendations for the Novo Nordisk ADR (NVO)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.19. Out of those 27 Wall Street analysts, 14 recommended a “Buy” rating, while 8 were in favor recommending the stock as a “Hold” and 3 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Cantor Fitzgerald on December 01, 2023 offering an Overweight rating for the stock and assigned a target price of $120 to it.
